Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Details

Instance of

clinical trial

Start time

June 2013

End time

April 2018

Country

Canada

Main subject

melanoma

clinical trial phase

phase II clinical trial

minimum age

18

number of participants

12

research intervention

(RS)-cyclophosphamide, fludarabine phosphate

study type

interventional study

title

Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma